RespireRx Pharmaceuticals Inc. (RSPI)

RespireRx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Selling, General & Admin	1.1	1.15	1.86	2.68	1.14	1.49
Research & Development	0.31	0.43	0.7	0.64	0.6	0.69
Other Operating Expenses	0	-0.07	0	0	0	0
Operating Expenses	1.41	1.58	2.56	3.32	1.74	2.18
Operating Income	-1.41	-1.58	-2.56	-3.32	-1.74	-2.18
Interest Income	0	0	0	0	0	0
Interest Expense	0.29	0.6	0.72	0.55	0.4	0.14
Other Expense / Income	-0.11	-0.08	-0.14	0.44	-0.03	-
Pretax Income	-1.81	-2.1	-3.14	-4.3	-2.12	-2.59
Income Tax	0.36	-0.08	0.72	0.55	0.4	0.28
Net Income	-1.94	-2.02	-3.87	-4.85	-2.52	-2.59
Shares Outstanding (Basic)	268	111	88	26	0	0
Shares Outstanding (Diluted)	268	111	88	26	0	0
Shares Change	124.49%	26.01%	241.69%	6515.29%	16.63%	38.57%
EPS (Basic)	-0.01	-0.02	-0.04	-0.19	-6.45	-7.73
EPS (Diluted)	-0.01	-0.02	-0.04	-0.19	-6.45	-7.73
Free Cash Flow	-0.25	-0.14	-0.96	-0.51	-0.49	-0.43
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.02	-1.25	-1.28
EBITDA	-1.48	-1.65	-2.56	-3.32	-1.74	-2.18
Depreciation & Amortization	390,911	390,911	552,787	374,080	215,575	8,378
EBIT	-390,912.15	-390,912.65	-552,789.56	-374,083.32	-215,576.74	-8,380.18

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.